Biotech Tracker
Trial resultsH1 2027a window, not a day

Felzartamab Phase 3 TRANSCEND data in antibody-mediated rejection

Biogen expects to report results from its Phase 3 study of felzartamab (anti-CD38) for Antibody-mediated rejection in kidney transplant recipients in the first half of 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary

DetailsClinical trial results · also called: readout / topline data
Company
Biogen Inc. BIIB
Drug
felzartamab (anti-CD38)
For
Antibody-mediated rejection in kidney transplant recipients
Stage
Phase 3 · the last stage before a drug can be approved
When
H1 2027 · the company gave a window, not a day; the calendar never invents one
Source note
Biogen accelerated expected Phase 3 TRANSCEND AMR data to the first half of 2027 (Q2 2026 business update).
Checked
Checked by a person when it was added
Check the sourcesdon’t take our word for it
Biogen Inc.
BIIB
4 upcoming · 7 past catalysts
More from BIIB
ConferenceBIIBBiogenH2 2026

Biogen presents data on Litifilimab for Cutaneous lupus erythematosus at a medical meeting in the second half of 2026 (no exact date yet). New numbers at a conference can move the stock as much as a formal announcement.

More details
Entry
Litifilimab AMETHYST 52-week Phase 2 CLE data at EADV 2026 · Data presented at a medical meeting
Drug
Litifilimab
For
Cutaneous lupus erythematosus
Stage
Phase 2/3 · a combined mid- to late-stage study
When
H2 2026 · the company gave a window, not a day
Source note
Biogen Q2 2026 earnings call (July 29, 2026): management plans to present 52-week Phase 2 AMETHYST CLE data at the EADV congress (fall 2026); exact month not stated by the company in the source.
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsBIIBBiogenQ4 2026

Biogen expects to report results from its Phase 3 study of litifilimab (BIIB059, anti-BDCA2) for Systemic lupus erythematosus in Q4 2026 (Oct–Dec) (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.

More details
Entry
Litifilimab Phase 3 TOPAZ-1 and TOPAZ-2 topline in systemic lupus · Clinical trial results (readout / topline data)
Drug
litifilimab (BIIB059, anti-BDCA2)
For
Systemic lupus erythematosus
Stage
Phase 3 · the last stage before a drug can be approved
When
Q4 2026 · the company gave a window, not a day
Source note
Biogen's Q2 2026 report (July 29, 2026) guides Phase 3 topline results from both TOPAZ SLE studies in the fourth quarter of 2026 — the company's most proximate binary pipeline event.
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsBIIBBiogenH1 2027

Biogen expects to report results from its Phase 3 study of litifilimab (BIIB059) for Cutaneous lupus erythematosus in the first half of 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.

More details
Entry
Litifilimab Phase 3 cutaneous lupus (CLE) data · Clinical trial results (readout / topline data)
Drug
litifilimab (BIIB059)
For
Cutaneous lupus erythematosus
Stage
Phase 3 · the last stage before a drug can be approved
When
H1 2027 · the company gave a window, not a day
Source note
Timing accelerated: Phase 3 CLE data now expected in the first half of 2027 (Biogen Q2 2026 business update).
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page